Verona Pharma PLC

Verona Pharma plc has completed its acquisition by Merck Sharp & Dohme LLC, with shareholders receiving $13.375 per ordinary share or $107 per ADS, leading to its delisting from Nasdaq.

Verona Pharma plc shareholders have overwhelmingly approved the proposed $10 billion acquisition by Merck, moving the transaction closer to its expected October 7, 2025 closing.

Verona Pharma plc has amended its employee change in control severance plan, extending benefit periods and revising resignation terms, contingent on a pending transaction.

Merck announced its definitive agreement to acquire Verona Pharma for approximately $10 billion, adding Ohtuvayre, a recently FDA-approved first-in-class COPD treatment, to its growing cardio-pulmonary pipeline.

Verona Pharma announces a successful first quarter in 2025, driven by strong Ohtuvayre sales, exceeding operating expenses, and providing a corporate update.

Verona Pharma reports successful passage of all resolutions at its 2025 Annual General Meeting of Shareholders held on April 24, 2025.

Verona Pharma achieved its first profitable quarter driven by strong Ohtuvayre sales, as its acquisition by Merck for $10 billion progresses towards a Q4 2025 close.

Verona Pharma's Q1 2025 results highlight a successful Ohtuvayre launch with $71.3 million in product sales and continued pipeline development.

Verona Pharma reports its first product sales of $5.6 million following the launch of Ohtuvayre in the third quarter of 2024, while also increasing research and development spending.

Verona Pharma's Q2 2024 report details the launch of Ohtuvayre, significant financial activities, and advancements in their clinical pipeline.

Verona Pharma's Q1 2024 results show increased spending on commercial preparations and a net loss of $25.8 million, while the company secures a new $250 million financing package.

Verona Pharma's 10-K filing summarizes the company's financial performance for 2024, emphasizing the FDA approval and commercial launch of Ohtuvayre, along with ongoing clinical development programs.

Verona Pharma plc filed its 10-K for the year ended December 31, 2023, outlining details of its share capital, American Depository Shares (ADS), and corporate governance.

Verona Pharma's General Counsel, Andrew Fisher, reported significant equity transactions following the company's acquisition via a Scheme of Arrangement.

Verona Pharma plc's President and CEO, David Zaccardelli, reported the disposition of shares and cash conversion of equity awards following the company's acquisition by Merck Sharp & Dohme LLC.

Verona Pharma's Chief Medical Officer, Kathleen A. Rickard, disposed of all her beneficial ownership in the company's shares and derivative securities following a scheme of arrangement related to an acquisition.

Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, reported the disposition of ordinary shares and conversion of equity awards into cash following the company's acquisition by Merck Sharp & Dohme LLC.

Verona Pharma director Michael Austwick reported the disposition of shares, RSUs, and options following the company's acquisition by Merck Sharp & Dohme LLC.

Verona Pharma director Anders Ullman reported the disposition of shares and derivative securities following the company's acquisition by Merck Sharp & Dohme LLC.

Verona Pharma provides employees with an update on the integration process with Merck, detailing retention agreements, severance, and the preliminary integration timeline.

Verona Pharma plc has filed a supplement to its definitive proxy statement, updating details on executive severance benefits, management arrangements, and the expiration of the HSR waiting period related to its Scheme of Arrangement.

Verona Pharma has entered into a definitive agreement to be acquired by Merck Sharp & Dohme LLC for $107 in cash per American Depositary Share, representing a significant premium to recent trading prices.

Merck & Co. Inc. is moving forward with the potential acquisition of Verona Pharma PLC, emphasizing employee retention and the strategic importance of Ohtuvayre.

Merck announced its intent to acquire Verona Pharma, integrating Verona's ensifentrine, a novel COPD treatment, into its portfolio, with ongoing clinical trials expected to continue uninterrupted.

Merck & Co., Inc. detailed its strategic rationale and integration plans for Verona Pharma, emphasizing the significant opportunity to address unmet needs in Chronic Obstructive Pulmonary Disease (COPD) with Ohtuvayre.

New Enterprise Associates and its affiliated entities have reduced their beneficial ownership in Verona Pharma plc to below the 5% reporting threshold through pro-rata distributions of shares.

Pentwater Capital Management LP and Matthew Halbower have fully divested their 6.1% stake in Verona Pharma plc.

Perceptive Advisors and related entities have reported ceasing beneficial ownership of Verona Pharma plc shares following its acquisition by Merck & Co., Inc.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a beneficial ownership of 1.2% in Verona Pharma PLC's American Depositary Shares.

BlackRock Portfolio Management LLC has reported a 6.0% beneficial ownership stake in Verona Pharma PLC, holding 27,645,624 common shares.

RA Capital Management and related entities filed an amendment to their Schedule 13G, disclosing a 0.7% beneficial ownership stake in Verona Pharma plc.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a 6.4% beneficial ownership stake in Verona Pharma plc as of June 30, 2025.